Development of New Tuberculosis Vaccines: A Global Perspective on Regulatory Issues

DOI: 10.1371/journal.pmed.0040252

Full-Text   Cite this paper   Add to My Lib

Abstract:

References

[1]	Brennan MJ (2005) The tuberculosis vaccine challenge. Tuberculosis 85: 7–12.
[2]	Fruth U, Young D (2004) Prospects for new TB vaccines: Stop TB Working Group on TB vaccine development. Int J Tuberc Lung Dis 8: 151–155.
[3]	Young D, Dye C (2006) The development and impact of tuberculosis vaccines. Cell 124: 683–687.
[4]	McShane H, Hill A (2005) Prime-boost immunisation strategies for tuberculosis. Microbes Infect 7: 962–967.
[5]	World Health Organization (2003) WHO guidelines on nonclinical evaluation of vaccines. Available: http://www.who.int/biologicals/publicati？ons/nonclinical_evaluation_vaccines_nov_？2003.pdf. Accessed 10 July 2007.
[6]	Brennan MJ, Sizemore C, Morris SL (2004) Tuberculosis vaccine development: Research, regulatory and clinical strategies. Expert Opin Biol Ther 4: 1493–1504.
[7]	Kamath AT, Fruth U, Brennan MJ, Dobbelaer R, Hubrechts P, et al. (2005) New live mycobacterial vaccines: The Geneva consensus on essential steps towards clinical development. Vaccine 23: 3753–3761.
[8]	Rowland SS, Mayner RL, Barker L (2005) Advancing TB vaccines to Phase I clinical trials in the US: Regulatory/manufacturing/licensing issues. Tuberculosis 85: 39–46.
[9]	Ibanga HB, Brookes RH, Hill PC, Owiafe PK, Fletcher HA, et al. (2006) Early clinical trials with a new tuberculosis vaccine, MVA85A, in tuberculosis-endemic countries: Issues in study design. Lancet Infect Dis 6: 522–528.
[10]	Skeiky YAW, Sadoff JC (2006) Advances in tuberculosis vaccine strategies. Nat Rev Microbiol 4: 469–476.
[11]	McShane H, Pathan AA, Sander CR, Keating SM, Gilbert SC, et al. (2004) Recombinant MVA85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans. Nature Med 10: 1240–1244.
[12]	Horwitz MA, Harth G, Dillon BJ, Maslesa-Galic' S (2000) Recombinant bacillus calmette-guerin (BCG) vaccines expressing the 30-kDa major secretory protein induce greater protective immunity against tuberculosis than conventional BCG vaccines in a highly susceptible animal model. Proc Natl Acad Sci U S A 97: 13853–13858.
[13]	Skeiky YA, Alderson MR, Overdale PJ, Guderian JA, Brandt L, et al. (2004) Differential immune responses and protective efficacy induced by components of a tuberculosis polyprotein vaccine, Mtb72F, delivered as naked DNA or recombinant protein. J Immunol 172: 7618–7628.
[14]	Weinrich Olsen A, van Pinxteren LA, Meng Okkels L, Birk Rasmussen P, Andersen P (2001) Protection of mice with a tuberculin subunit vaccine based on a fusion protein of antigen 85B and esat-6. Infect Immun 69: 2773–2778.
[15]	Andersen P, Doherty TM (2005) TB subunit vaccines—Putting the pieces together. Microbes Infect 7: 911–921.
[16]	Hess J, Miko D, Catic A, Lehmensiek V, Russell DG, et al. (1998) Bacille Calmette-Guérin strains secreting listeriolysis of . Proc Natl Acad Sci U S A 95: 5299–5304.
[17]	Sambandamurthy VK, Jacobs WR Jr (2005) Live attenuated mutants of as candidate vaccines against tuberculosis. Microbes Infect 7: 955–959.
[18]	Pym AS, Brodin P, Mailessi L, Brosch R, Demangel C, et al. (2003) Recombinant BCG exporting ESAT-6 confers enhanced protection against tuberculosis. Nat Med 9: 533–539.
[19]	Perez E, Samper S, Bordas Y, Guilhot C, Gicquel B, et al. (2001) An essential role for phoP in virulence. Mol Microbiol 41: 179–187.

Full-Text